Ben Mullish
@bhmullish.bsky.social
MRC Clinician Scientist Fellow and Honorary Consultant in Hepatology and Gastroenterology, based at Imperial College London. All comments in a personal capacity.
Reposted by Ben Mullish
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
www.thelancet.com/journals/ecl...
#GastroSky #MedSky #IBDSky
www.thelancet.com/journals/ecl...
#GastroSky #MedSky #IBDSky
A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
Treatment efficacy in similar WH and SA IBD patients recruited to the UK IBD BioResource
is unaffected by ethnicity but patients from SA ethnic backgrounds are at increased
risk of developing pancreat...
www.thelancet.com
November 18, 2025 at 2:33 PM
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
www.thelancet.com/journals/ecl...
#GastroSky #MedSky #IBDSky
www.thelancet.com/journals/ecl...
#GastroSky #MedSky #IBDSky
Great to see out this study from Sharmili Balarajah and Laura Martinez-Gili @imperialmdr.bsky.social, working with the #IBD @nihrbioresource.bsky.social, comparing outcomes with #IBD therapies in White and South Asian patients, now in @eclinicalmed.bsky.social: www.sciencedirect.com/science/arti...
A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
While ethnic differences in IBD phenotype are recognised, the comparative efficacy and safety of common IBD therapies across ethnically diverse popula…
www.sciencedirect.com
November 18, 2025 at 6:55 AM
Great to see out this study from Sharmili Balarajah and Laura Martinez-Gili @imperialmdr.bsky.social, working with the #IBD @nihrbioresource.bsky.social, comparing outcomes with #IBD therapies in White and South Asian patients, now in @eclinicalmed.bsky.social: www.sciencedirect.com/science/arti...
Very pleased to see this practical guide to #nutrition in #cirrhosis out in #FrontlineGastroenterology: fg.bmj.com/content/earl.... Thanks to Luke Tyson for leading the group! #liversky
November 5, 2025 at 10:17 AM
Very pleased to see this practical guide to #nutrition in #cirrhosis out in #FrontlineGastroenterology: fg.bmj.com/content/earl.... Thanks to Luke Tyson for leading the group! #liversky
Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians
September 11, 2025 at 3:00 PM
Honoured to speak on #FMT #LBPs at the #EHMSG meeting today in session with Nicolas Benech and Jens Walter. Thanks to Gianluca Ianiro for organising, and for even getting a @nobelprize.bsky.social winner for Physics to speak to us, Giorgio Parisi! @imperialmdr.bsky.social #microbiomeclinicians
Reposted by Ben Mullish
www.sciencedirect.com/science/arti... - we used an AMS approach to operationalise & formalise a structured approach to FMT @imperialcollegeldn.bsky.social @imperialnhs.bsky.social
Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service
www.sciencedirect.com
August 10, 2025 at 1:46 PM
www.sciencedirect.com/science/arti... - we used an AMS approach to operationalise & formalise a structured approach to FMT @imperialcollegeldn.bsky.social @imperialnhs.bsky.social
Out now from us in @thejhi.bsky.social - operational considerations in running an #NHS #FMT service: www.sciencedirect.com/science/arti... @imperialmdr.bsky.social @imperialbrc.bsky.social #GastroSky #MicroSky #IDSky
Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service
www.sciencedirect.com
August 10, 2025 at 3:56 AM
Out now from us in @thejhi.bsky.social - operational considerations in running an #NHS #FMT service: www.sciencedirect.com/science/arti... @imperialmdr.bsky.social @imperialbrc.bsky.social #GastroSky #MicroSky #IDSky
Very pleased to see this out in @cmijournal.bsky.social - what non-antimicrobial options are there for recurrent #UTI, and what might be the role for #FMT? www.clinicalmicrobiologyandinfection.com/article/S119... @rohmaghani.bsky.social @imperialmdr.bsky.social @imperialbrc.bsky.social #MicroSky
https://clinicalmicrobiologyandinfection.com/article/S1198-…
July 29, 2025 at 10:21 PM
Very pleased to see this out in @cmijournal.bsky.social - what non-antimicrobial options are there for recurrent #UTI, and what might be the role for #FMT? www.clinicalmicrobiologyandinfection.com/article/S119... @rohmaghani.bsky.social @imperialmdr.bsky.social @imperialbrc.bsky.social #MicroSky
Reposted by Ben Mullish
We’ve also written a Behind the Paper blog post to accompany our article, which you can find here: go.nature.com/401ctsa
Antibiotics fuel the rise of vancomycin-resistant enterococci intestinal colonisation by remodelling the metabolic landscape of the gut microbiome
Antibiotics save lives- but also reshape the gut microbiome, unintentionally promoting VRE colonisation. This study reveals how antibiotic-driven metabolic shifts promote VRE expansion and highlights ...
go.nature.com
July 22, 2025 at 9:12 AM
We’ve also written a Behind the Paper blog post to accompany our article, which you can find here: go.nature.com/401ctsa
Great to see this work from Shiv Radhakrishnan and colleagues out in #GutMicrobes - using network analysis to explore #microbiome #metabolome interactions in an #IBD inception cohort: doi.org/10.1080/1949... @imperialmdr.bsky.social @imperialhepatology.bsky.social #IBDSky #GISky
doi.org
July 18, 2025 at 12:12 PM
Great to see this work from Shiv Radhakrishnan and colleagues out in #GutMicrobes - using network analysis to explore #microbiome #metabolome interactions in an #IBD inception cohort: doi.org/10.1080/1949... @imperialmdr.bsky.social @imperialhepatology.bsky.social #IBDSky #GISky
Reposted by Ben Mullish
So excited to share a new paper from my lab just published in Nature Communications! We showed that vancomycin-resistant enterococci (VRE) occupied distinct intestinal niches in the antibiotic-treated intestine. doi.org/10.1038/s414... Amazing work by first author Olivia King and colleagues!
Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation - Nature Communications
Here, the authors show that vancomycin-resistant enterococci grow in the antibiotic-treated gut microbiome by utilising enriched nutrients in the presence of reduced concentrations of inhibitory micro...
doi.org
July 14, 2025 at 9:11 AM
So excited to share a new paper from my lab just published in Nature Communications! We showed that vancomycin-resistant enterococci (VRE) occupied distinct intestinal niches in the antibiotic-treated intestine. doi.org/10.1038/s414... Amazing work by first author Olivia King and colleagues!
Reposted by Ben Mullish
Vancomycin-resistant 𝙀𝙣𝙩𝙚𝙧𝙤𝙘𝙤𝙘𝙘𝙪𝙨 𝙛𝙖𝙚𝙘𝙞𝙪𝙢 (VRE) thrives in the antibiotic-perturbed gut
VRE gobbles up enriched sugars and amino acids, and loss of short-chain fatty acids (acetate, propionate, butyrate) eliminates natural growth brakes
Therapeutic angle: Prebiotic SCFA mixtures block VRE growth!
VRE gobbles up enriched sugars and amino acids, and loss of short-chain fatty acids (acetate, propionate, butyrate) eliminates natural growth brakes
Therapeutic angle: Prebiotic SCFA mixtures block VRE growth!
Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation - Nature Communications
Here, the authors show that vancomycin-resistant enterococci grow in the antibiotic-treated gut microbiome by utilising enriched nutrients in the presence of reduced concentrations of inhibitory micro...
www.nature.com
July 11, 2025 at 1:08 PM
Vancomycin-resistant 𝙀𝙣𝙩𝙚𝙧𝙤𝙘𝙤𝙘𝙘𝙪𝙨 𝙛𝙖𝙚𝙘𝙞𝙪𝙢 (VRE) thrives in the antibiotic-perturbed gut
VRE gobbles up enriched sugars and amino acids, and loss of short-chain fatty acids (acetate, propionate, butyrate) eliminates natural growth brakes
Therapeutic angle: Prebiotic SCFA mixtures block VRE growth!
VRE gobbles up enriched sugars and amino acids, and loss of short-chain fatty acids (acetate, propionate, butyrate) eliminates natural growth brakes
Therapeutic angle: Prebiotic SCFA mixtures block VRE growth!
A great privilege to work with @julieakmcdonald.bsky.social lab on this new paper, now out in @natureportfolio.nature.com Communications - how #antibiotic-related changes in gut #nutrients and #metabolites promote #VRE colonisation: doi.org/10.1038/s414... @imperialmdr.bsky.social
https://doi.org/10.1038/s41467…
July 10, 2025 at 8:57 PM
A great privilege to work with @julieakmcdonald.bsky.social lab on this new paper, now out in @natureportfolio.nature.com Communications - how #antibiotic-related changes in gut #nutrients and #metabolites promote #VRE colonisation: doi.org/10.1038/s414... @imperialmdr.bsky.social
Honoured to to be part of this Future of Hepatology session at @easlnews.bsky.social #EASL2025, discussing the promise of #microbiome related therapies in #PSC #cholestatic liver disease - where have we come since the original #FMT #PSC pilot study by @DrAllegrettiIBD? doi.org/10.14309/ajg...
May 10, 2025 at 6:33 AM
Honoured to to be part of this Future of Hepatology session at @easlnews.bsky.social #EASL2025, discussing the promise of #microbiome related therapies in #PSC #cholestatic liver disease - where have we come since the original #FMT #PSC pilot study by @DrAllegrettiIBD? doi.org/10.14309/ajg...
Reposted by Ben Mullish
Delighted to welcome Manchester Royal Infirmary onto the #MAST trial as our seventh site! Pleased to be able to expand our coverage for this important trial of #GutMicrobiome manipulation with #IMT #FMT before #HCT; find out more here: www.imperial.ac.uk/metabolism-d... @imperialmdr.bsky.social
MAST study
The Imperial MAST study: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) study.
www.imperial.ac.uk
March 28, 2025 at 9:31 AM
Delighted to welcome Manchester Royal Infirmary onto the #MAST trial as our seventh site! Pleased to be able to expand our coverage for this important trial of #GutMicrobiome manipulation with #IMT #FMT before #HCT; find out more here: www.imperial.ac.uk/metabolism-d... @imperialmdr.bsky.social
Reposted by Ben Mullish
Want to know more about why we are looking at the #GutMicrobiome #IMT #HCT as therapy? Find out even more here: youtu.be/zDd1qdVCa6A?...
youtu.be
March 19, 2025 at 5:38 PM
Want to know more about why we are looking at the #GutMicrobiome #IMT #HCT as therapy? Find out even more here: youtu.be/zDd1qdVCa6A?...
Reposted by Ben Mullish
The #MAST trial is pushing forward, investigating the impact of #IMT #FMT prior to #HCT in seven UK centres #HaemSky #MicrobiomeSky #GastroSky @imperialmdr.bsky.social @bloodcanceruk.bsky.social ruk.bsky.social @anthonynolan.bsky.social. Find out more from our poster or our website: rb.gy/myizsb
March 19, 2025 at 5:37 PM
The #MAST trial is pushing forward, investigating the impact of #IMT #FMT prior to #HCT in seven UK centres #HaemSky #MicrobiomeSky #GastroSky @imperialmdr.bsky.social @bloodcanceruk.bsky.social ruk.bsky.social @anthonynolan.bsky.social. Find out more from our poster or our website: rb.gy/myizsb
Reposted by Ben Mullish
The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort https://www.medrxiv.org/content/10.1101/2025.03.09.25323328v1
March 13, 2025 at 10:02 AM
The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort https://www.medrxiv.org/content/10.1101/2025.03.09.25323328v1
A great first day at the #BSG #GutMicrobiome event, covering everything from early life @halllab.bsky.social, to #liver @debbieshawcross.bsky.social, to #cancer @jameskinross.bsky.social, and culminating in a tour de force on #IBD and the #microbiome in clinical practice from Prof Harry Sokol
March 6, 2025 at 9:46 PM
A great first day at the #BSG #GutMicrobiome event, covering everything from early life @halllab.bsky.social, to #liver @debbieshawcross.bsky.social, to #cancer @jameskinross.bsky.social, and culminating in a tour de force on #IBD and the #microbiome in clinical practice from Prof Harry Sokol
Reposted by Ben Mullish
MAST is moving onwards and upwards and now up to 18 recruited patients. We push on, hoping to see how gut #microbiome manipulation with #IMT #FMT can help our patients with #BloodCancer #HCT @bloodcanceruk.bsky.social @anthonynolan.bsky.social
January 22, 2025 at 11:10 AM
MAST is moving onwards and upwards and now up to 18 recruited patients. We push on, hoping to see how gut #microbiome manipulation with #IMT #FMT can help our patients with #BloodCancer #HCT @bloodcanceruk.bsky.social @anthonynolan.bsky.social
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...
doi.org
January 7, 2025 at 7:30 AM
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
Great that the #MAST trial is moving ahead, and really hoping that this shows the #microbiome as a route to give new treatment prospects to #HCT #BloodCancer patients @bloodcanceruk.bsky.social @cancerresearchuk.org
Now out - protocol paper for the #MAST trial, exploring #IMT #FMT to #prehabilitate the #GutMicrobiome in #BloodCancer patients receiving #HCT, now in #BMJOpen: doi.org/10.1136/bmjo... . Grateful to #MRC #DPFS for funding and #EnteroBiotix as project partners #HaemSky #MicrobiomeSky #GastroSky
December 22, 2024 at 7:36 PM
Great that the #MAST trial is moving ahead, and really hoping that this shows the #microbiome as a route to give new treatment prospects to #HCT #BloodCancer patients @bloodcanceruk.bsky.social @cancerresearchuk.org
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
academic.oup.com
December 14, 2024 at 11:53 AM
Great work by Nabil Quraishi, Palak Trivedi and many others - unravelling the positive impact of #vancomycin in #PSC #IBD by altering interactions between the host, #microbiome, and #metabolome. Now in #JCC: academic.oup.com/ecco-jcc/adv... #GastroSky
Great to work with the lab of @julieakmcdonald.bsky.social and see this preprint out on @biorxivpreprint.bsky.social, looking at how nutrient availability and microbial #metabolites impact #VRE colonisation in the #antibiotic treated gut: www.biorxiv.org/content/10.1... #MicroSky #GastroSky
December 13, 2024 at 3:27 PM
Great to work with the lab of @julieakmcdonald.bsky.social and see this preprint out on @biorxivpreprint.bsky.social, looking at how nutrient availability and microbial #metabolites impact #VRE colonisation in the #antibiotic treated gut: www.biorxiv.org/content/10.1... #MicroSky #GastroSky
Great work by Sharmili Balarajah with #ImperialMDR colleagues and the @nihr.bsky.social #IBD Bioresource team, now in press in #JCC - exploring differences in #IBD phenotypes and treatment approaches between White and South Asian patients in the UK: academic.oup.com/ecco-jcc/adv...
Diverse phenotypes, consistent treatment: a study of 30,997 South Asian and White IBD patients using the UK IBD BioResource
AbstractObjective. To evaluate South Asian (SA) and White (WH) inflammatory bowel disease (IBD) phenotypes, and to explore treatment approach variations be
academic.oup.com
December 7, 2024 at 1:24 PM
Great work by Sharmili Balarajah with #ImperialMDR colleagues and the @nihr.bsky.social #IBD Bioresource team, now in press in #JCC - exploring differences in #IBD phenotypes and treatment approaches between White and South Asian patients in the UK: academic.oup.com/ecco-jcc/adv...
Thanks to Gianluca Ianiro for co-ordinating the international consensus statement on #microbiome testing in clinical practice, now in Lancet GastroHep - an assessment of where we are and where we hope to go: doi.org/10.1016/S246... #GastroSky #MedSky
December 6, 2024 at 6:49 AM
Thanks to Gianluca Ianiro for co-ordinating the international consensus statement on #microbiome testing in clinical practice, now in Lancet GastroHep - an assessment of where we are and where we hope to go: doi.org/10.1016/S246... #GastroSky #MedSky